BioSpace News Archive

Calliditas Therapeutics AB (NASDAQ: CALT) (NASDAQ Stockholm: CALTX) (“Calliditas”), today announced the presentations of new biomarker and subgroup analyses from the Phase 3 NefIgArd study with Nefecon (TARPEYO® (budesonide) delayed release capsules/Kinpeygo®) in adults with Primary IgA nephropathy (IgAN).

Fuse Oncology (Fuse) a trailblazing leader in radiation oncology software solutions, unveils their latest pioneering product, FuseDocs, today.

Spexis AG, a clinical-stage biopharmaceutical company focused on macrocycle therapeutics for rare diseases and oncology, announced its financial results for the first half of 2023 and provided a strategic business update.

Annexin Pharmaceuticals announces important progress in the company’s preclinical cancer research where the drug candidate ANXV has shown promising results as a transporter of chemotherapy drugs to kill cancer cells.

Swedish Orphan Biovitrum AB has, as previously announced, carried out a rights issue of common shares, which has resulted in changes in the number of shares and votes in Sobi.

SOPHiA GENETICS announced that Shaare Zedek, the largest multi-disciplinary medical center in Jerusalem, is now live on the SOPHiA DDM™ Platform.

Synlogic, Inc. announced the pricing of an underwritten public offering of 7,394,363 shares of common stock and accompanying common warrants to purchase up to an aggregate of 7,394,363 shares of common stock.

Ginkgo Bioworks and Texas A&M University announced they have been jointly awarded a research grant from the U.S. Department of Agriculture’s Animal and Plant Health Inspection Service via the National Institute of Food and Agriculture, Agriculture and Food Research Initiative to study SARS-CoV-2 in white-tailed deer populations in Texas.

Kazia Therapeutics Limited is pleased to announce that data from an ongoing Phase II study of paxalisib, an investigational drug for the treatment of diffuse intrinsic pontine glioma and other diffuse midline gliomas, sponsored by the Pacific Pediatric Neuro-Oncology Consortium, has been awarded a late breaking oral presentation at the 2023 Society for Neuro-Oncology Annual Meeting.

Theralase® Technologies Inc. is a clinical stage pharmaceutical company that is dedicated to the research and development of light and radiation activated Photo Dynamic Compounds, their associated drug formulations and the light systems that activate them.